AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation
暂无分享,去创建一个
J. Mansfield | J. Eastham‐Anderson | C. Lamb | J. Kirby | M. Keir | W. Faubion | A. Long | R. Ichikawa | L. Raffals | A. Scherl | Miriam R Bennett | Ryan Ichikawa
[1] J. Mansfield,et al. αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis , 2016, Journal of Crohn's & colitis.
[2] M. Keir,et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC , 2016, Gut.
[3] M. Neurath,et al. Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo , 2016, Gut.
[4] John T. Chang,et al. The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.
[5] Stefan Schreiber,et al. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. , 2016, Gastroenterology.
[6] B. Yaspan,et al. Stratified medicine in inflammatory disorders: From theory to practice. , 2015, Clinical immunology.
[7] L. Stitt,et al. Development and validation of a histological index for UC , 2015, Gut.
[8] S. Vermeire,et al. 901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study , 2015 .
[9] John T. Chang,et al. Validation of Gene Expression Biomarker Analysis for Biopsy-based Clinical Trials in Crohn's Disease , 2015, Inflammatory bowel diseases.
[10] M. Groenen,et al. Naive T Cells in the Gut of Newly Diagnosed, Untreated Adult Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.
[11] J. Xu,et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.
[12] J. Mansfield,et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.
[13] J. Fletcher,et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.
[14] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[15] P. Rutgeerts,et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.
[16] A. Huisman,et al. Automatic Nuclei Segmentation in H&E Stained Breast Cancer Histopathology Images , 2013, PloS one.
[17] M. Colonna,et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells. , 2013, Immunity.
[18] W. Agace,et al. Targeting T‐cell migration in inflammatory bowel disease , 2012, Journal of internal medicine.
[19] K. Ley,et al. Role of beta7 integrins in intestinal lymphocyte homing and retention. , 2009, Current molecular medicine.
[20] P. Rutgeerts,et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.
[21] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[22] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[23] P. Rutgeerts,et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.
[24] Y. Fujiwara,et al. Differential expression of homing receptor CD103 on lamina propria lymphocytes and association of CD103 with epithelial adhesion molecules in inflammatory bowel disease. , 2003, International journal of molecular medicine.
[25] B. Rocha,et al. A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL‐10 secretion and T cell homeostasis , 2003, European journal of immunology.
[26] Larry V McIntire,et al. Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[27] J. Kirby,et al. The number of intraepithelial T cells decreases from ascending colon to rectum. , 2003, Journal of clinical pathology.
[28] Richard O Hynes,et al. Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.
[29] Alf Hamann,et al. Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[30] H. Van Vlierberghe,et al. Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. , 1998, Acta gastro-enterologica Belgica.
[31] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[32] R. Johnson,et al. Characterization of gut-associated lymphoid tissue (GALT) of normal rhesus macaques. , 1997, Clinical immunology and immunopathology.
[33] E. Ebert,et al. Spontaneous cytotoxicity of intestinal intraepithelial lymphocytes: clues to the mechanism , 1993, Clinical and experimental immunology.
[34] T. Arndt,et al. In vivo , 2019, Springer Reference Medizin.
[35] B. Sands,et al. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. , 2018, Gastroenterology.
[36] B. Sands,et al. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.
[37] P. Rutgeerts,et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.
[38] B. Warner,et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.
[39] E. Szigethy,et al. Inflammatory bowel disease. , 2011, Pediatric clinics of North America.
[40] A. Scheffold,et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. , 2002, Proceedings of the National Academy of Sciences of the United States of America.